Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rocket Pharmaceuticals Inc
(NQ:
RCKT
)
18.97
+0.37 (+1.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rocket Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know
August 09, 2022
Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals (NASDAQ:RCKT) and raise its price target from $22.00 to $24.00. Shares of Rocket Pharmaceuticals are trading up...
Via
Benzinga
Rocket Pharmaceuticals: Q2 Earnings Insights
August 08, 2022
Rocket Pharmaceuticals (NASDAQ:RCKT) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
August 08, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities
July 27, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Rocket Pharmaceuticals
July 26, 2022
Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
4 Analysts Have This to Say About Rocket Pharmaceuticals
July 06, 2022
Within the last quarter, Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings:
Via
Benzinga
Why Jim Cramer Says This Stock Is 'Definitely A Buy'
July 20, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is with Tellurian Inc. (NYSE: TELL).
Via
Benzinga
Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies
July 08, 2022
Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
July 08, 2022
Via
Benzinga
Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder
May 19, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 26, 2022
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Via
Benzinga
Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference
July 08, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Analyst Ratings for Rocket Pharmaceuticals
May 20, 2022
Over the past 3 months, 4 analysts have published their opinion on Rocket Pharmaceuticals (NASDAQ:RCKT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
May 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 19, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
May 16, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
May 11, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
May 05, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
April 27, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
April 19, 2022
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was...
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
April 21, 2022
On Thursday, 236 companies hit new 52-week lows.
Via
Benzinga
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
March 29, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors
March 14, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
February 24, 2022
From
Rocket Pharmaceuticals
Via
Business Wire
Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Executives Buy Around $64M Of 3 Stocks
February 09, 2022
US stock futures traded higher this morning, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs
January 11, 2022
From
Rocket Pharmaceuticals
Via
Business Wire
Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
December 27, 2021
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout...
Via
Benzinga
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
December 13, 2021
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.